Ollin Biosciences Raises $330M for Vision Drug Development

Ollin Biosciences has successfully closed an oversubscribed $330 million Series B financing round, signaling strong investor confidence in its pipeline of novel therapies for vision-threatening conditions. The substantial capital infusion is earmarked to propel the global Phase 3 development of its lead candidate, OLN324, targeting diabetic macular edema (DME) and wet age-related macular degeneration (AMD).

The financing round saw significant participation from both new and existing backers. TCGX and founding investor ARCH Venture Partners co-led the effort. The syndicate also includes prominent names such as a16z Bio+Health, Blackstone Multi-Asset Investing, Commodore Capital, Canada Pension Plan Investment Board, RA Capital Management, accounts advised by T. Rowe Price Investment Management, the sovereign wealth fund Mubadala Capital, and Monograph Capital. This broad investor base underscores the perceived potential of Ollin's therapeutic approach within the lucrative ophthalmology market, estimated to be worth billions.

OLN324, a next-generation bispecific antibody targeting both VEGF and Ang2 pathways, has demonstrated promising results in earlier studies. Notably, a 164-patient JADE clinical trial showed that OLN324 achieved superior and more rapid improvements in retinal anatomy compared to the existing standard of care, faricimab, in both DME and wet AMD patient populations. The drug's design emphasizes enhanced Ang2 potency, increased molar dosing, and a smaller protein format, aiming for a best-in-class profile.

Beyond its lead asset, the substantial funding will also accelerate the advancement of OLN102, a distinct bispecific antibody targeting TSHR/IGF-1R. This candidate is being developed for thyroid eye disease and Graves' disease and is slated to enter clinical trials this year. Ollin's strategy focuses on acquiring and developing therapies that can significantly alter treatment paradigms for debilitating eye conditions.

With positive End-of-Phase 2 feedback from the U.S. Food and Drug Administration and scientific advice from the European Medicines Agency, Ollin Biosciences is preparing to initiate global Phase 3 trials for OLN324 in the latter half of 2026. The company, founded in 2023, is rapidly positioning itself as a key player in the ophthalmology space, driven by a strong scientific foundation and a clear development roadmap. The successful Series B round provides the necessary capital to navigate these critical late-stage clinical studies and further solidify its market presence.

The strategic importance of this funding cannot be overstated. The $330 million injection equips Ollin Biosciences with the resources to execute its ambitious clinical development plans, particularly for OLN324, which addresses significant unmet needs in retinal vascular diseases. The company's focus on differentiated, bispecific antibody technology, coupled with compelling early clinical data, has attracted a high-caliber investor group, setting the stage for potential future milestones and market entry.